Cardiovascular Manifestations and Therapy Options for Systemic Lupus Erythematosus: A Systemic Literature Review

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune
multi-systemic disease; it is a controlled disease but is
not curable. SLE affects different systems in the body,
such as cardiac, renal, respiratory, hematology,
neurology, and rheumatology. It can cause various
problems in the heart, lungs, and joints. This Systemic
review researched articles from 3 databases: PubMed,
Google Scholar, and PubMed Central in June 2022. We
did this systemic review using Prisma guidelines. We
collected this systemic review in the last five years. Free
full articles randomized controlled trial (RCT), systemic
review articles, and English language included. Other
languages and articles earlier than 2017. Joanna Briggs
Institute (JBI) checklist, Assessment of Multiple
Systemic Reviews 2 (AMSTAR), and Scale for the
Assessment of Multiple Systemic Reviews 2 (SANRA)
are used to check for quality assessment. In the
systemic review, the initial search generated 516
articles. They included 13 in the final selection; six were
case reports, two were systemic reviews, three of them
retrospective studies, and two were literature reviews.
In this Systemic review, we will focus on the cardiac
manifestations associated with systemic lupus
erythematosus and use Hydroxychloroquine to prevent
the deterioration of systemic lupus erythematosus and
decrease the incidence rate cardiac problems. It
discovered a decrease in the incidence rate of cardiac
manifestations. It found that hydroxychloroquine is
effective in the treatment of systemic lupus
erythematosus patients. Not only that, but they found
that Hydroxychloroquine effectively treats systemic
lupus erythematosus patients and limits cardiac risk
factors. We need further studies and research to
understand the effect of systemic lupus erythematosus
on the cardiac system and the effects of
Hydroxychloroquine on decreasing the impact of
systemic lupus erythematosus on the heart.